Cytokines, like interleukin 1 beta (IL1b), play an important role in inflammation and immune responses. Canakinumab is a moloconal antibody, targeting IL1b, used to treat auto-inflammatory syndromes in children. Canakinumab may reduce inflammation in Duchenne.
A Phase 1/2 study is actively recruiting participants.
This program is sponsored by Children’s Research Institute.
|Single Escalating Dose Pilot Trial of Canakinumab (ILARIS®) in Duchenne Muscular Dystrophy|